{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:05:54Z","timestamp":1784822754987,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118262","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:09:18Z","timestamp":1750208958000},"page":"118262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comparative assessment of binding and functional differences of clinical antibodies targeting \u03b1-synuclein in cellular models of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"189","author":[{"given":"YuTing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isin","family":"Dalkilic-Liddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-9798","authenticated-orcid":false,"given":"Benjamin A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0005-7305","authenticated-orcid":false,"given":"Chao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4136-4367","authenticated-orcid":false,"given":"Daniel J.","family":"Apicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Hrdlicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-9087","authenticated-orcid":false,"given":"Andreas","family":"Weihofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0389-8891","authenticated-orcid":false,"given":"Warren D.","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Plowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0802-0052","authenticated-orcid":false,"given":"Paul H.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Pepinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118262_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","article-title":"Description of Parkinson\u2019s disease as a clinical syndrome","volume":"991","author":"Fahn","year":"2003","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118262_bib2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mds.27340","article-title":"Medical and surgical management of advanced Parkinson's disease","volume":"33","author":"Antonini","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2025.118262_bib3","doi-asserted-by":"crossref","unstructured":"L.M.A. Oliveira, T. Gasser, R. Edwards, M. Zweckstetter, R. Melki, L. Stefanis, H.A. Lashuel, D. Sulzer, K. Vekrellis, G.M. Halliday, J.J. Tomlinson, M. Schlossmacher, P.H. Jensen, J. Schulze-Hentrich, O. Riess, W.D. Hirst, O. El-Agnaf, B. Mollenhauer, P. Lansbury, T.F. Outeiro, Alpha-synuclein research: defining strategic moves in the battle against Parkinson\u2019s disease NPJ Parkinsons Dis, 7: 652021.","DOI":"10.1038\/s41531-021-00203-9"},{"key":"10.1016\/j.biopha.2025.118262_bib4","doi-asserted-by":"crossref","first-page":"13709","DOI":"10.1021\/bi961799n","article-title":"NACP, A protein implicated in Alzheimer's disease and learning, is natively unfolded","volume":"35","author":"Weinreb","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2025.118262_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0896-6273(95)90040-3","article-title":"Characterization of a novel protein regulated during the critical period for song learning in the zebra finch","volume":"15","author":"George","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2025.118262_bib6","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118262_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding \u03b1-synuclein in Parkinson's disease","volume":"18","author":"Kr\u00fcger","year":"1998","journal-title":"Nat. Genet"},{"key":"10.1016\/j.biopha.2025.118262_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of \u03b1-synuclein causes Parkinson and lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2025.118262_bib9","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1038\/ncomms4827","article-title":"Direct observation of the three regions in \u03b1-synuclein that determine its membrane-bound behaviour","volume":"5","author":"Fusco","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118262_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12563","article-title":"Structural basis of synaptic vesicle assembly promoted by \u03b1-synuclein","volume":"7","author":"Fusco","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118262_bib11","first-page":"115","article-title":"Role of post-translational modifications in modulating the structure, function and toxicity of a-synuclein: implications for Parkinson\u2019s disease pathogenesis and therapies","volume":"183","author":"Oueslati","year":"2010","journal-title":"Prog. Basic Res"},{"key":"10.1016\/j.biopha.2025.118262_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.14283\/jpad.2023.6","article-title":"Investigating partially discordant results in phase 3 studies of Aducanumab","volume":"10","author":"Mallinckrodt","year":"2023","journal-title":"Prev. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118262_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118262_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118262_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.37349\/ent.2023.00048","article-title":"Targeting \u03b1-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson\u2019s disease","author":"Henriquez","year":"2023","journal-title":"Explor Neuroprot Ther. 3"},{"key":"10.1016\/j.biopha.2025.118262_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118262_bib17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2025.118262_bib18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118262_bib19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson's disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118262_bib20","article-title":"Quantification of cinpanemab (BIIB054) binding to \u03b1- synuclein in cerebrospinal fluid of phase 1 single ascending dose samples","author":"Liu","year":"2024","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118262_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1994690","article-title":"Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies","volume":"13","author":"Fjord-Larsen","year":"2021","journal-title":"Mabs"},{"key":"10.1016\/j.biopha.2025.118262_bib22","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.29784","article-title":"Randomized Phase I trial of the \u03b1-synuclein antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2025.118262_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118262_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2014.05.009","article-title":"Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice","volume":"69","author":"Lindstr\u00f6m","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118262_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105543","article-title":"ABBV-0805, a novel antibody selective for soluble aggregated \u03b1-synuclein, prolongs lifespan and prevents buildup of \u03b1-synuclein pathology in mouse models of Parkinson\u2019s disease","volume":"161","author":"Nordstr\u00f6m","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118262_bib26","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"\u03b1-synuclein immunotherapy blocks uptake and templated propagation of misfolded \u03b1-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118262_bib27","article-title":"Safety and efficacy of the anti-alpha synuclein monoclonal antibody Lu AF82422 for the treatment of patients with MSA: results from the phase 2 AMULET trial. [abstract]","volume":"39","author":"Singer","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2025.118262_bib28","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","article-title":"Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat. Med."},{"issue":"560","key":"10.1016\/j.biopha.2025.118262_bib29","article-title":"Antibodies to alpha-synuclein and uses thereof","volume":"11","author":"Schofield","year":"2024","journal-title":"US Pat."},{"key":"10.1016\/j.biopha.2025.118262_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2022.136491","article-title":"Lysophosphatidylcholine acyltransferase 1 promotes pathology and toxicity in two distinct cell-based alpha-synuclein models","volume":"772","author":"Nicholatos","year":"2022","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2025.118262_bib31","doi-asserted-by":"crossref","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","article-title":"Proteopathic tau seeding predicts tauopathy in vivo","volume":"111","author":"Holmes","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"106","key":"10.1016\/j.biopha.2025.118262_bib32","doi-asserted-by":"crossref","DOI":"10.3791\/53205","article-title":"Sensitive detection of proteopathic seeding activity with FRET flow cytometry","author":"Furman","year":"2015","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2025.118262_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105477","article-title":"DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease","volume":"158","author":"Arkan","year":"2021","journal-title":"Neurobiol. Dis."},{"issue":"219","key":"10.1016\/j.biopha.2025.118262_bib34","doi-asserted-by":"crossref","first-page":"l2","DOI":"10.1126\/stke.2192004pl2","article-title":"Computational alanine scanning of protein-protein interfaces","volume":"2004","author":"Kortemme","year":"2004","journal-title":"Sci. STKE"},{"key":"10.1016\/j.biopha.2025.118262_bib35","doi-asserted-by":"crossref","first-page":"18949","DOI":"10.1073\/pnas.1115898108","article-title":"Algorithm discovery by protein folding game players","volume":"108","author":"Khatib","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118262_bib36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jmb.2010.11.008","article-title":"Alternate states of proteins revealed by detailed energy landscape mapping","volume":"405","author":"Tyka","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118262_bib37","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1126\/science.1089427","article-title":"Design of a novel globular protein fold with atomic-level accuracy","volume":"302","author":"Kuhlman","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118262_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-2836(03)00888-X","article-title":"A large scale test of computational protein design: folding and stability of nine completely redesigned globular proteins","volume":"332","author":"Dantas","year":"2003","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118262_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12987-018-0093-6","article-title":"Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration","volume":"15","author":"Wang","year":"2018","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.biopha.2025.118262_bib40","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2025.118262_bib41","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1074\/jbc.RA118.004471","article-title":"Parkinson\u2019s disease and multiple system atrophy have distinct \u03b1-synuclein seed characteristics","volume":"294","author":"Yamasaki","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118262_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0091-679X(08)85016-9","article-title":"Engineering FRET constructs using CFP and YFP","volume":"85","author":"Shimozono","year":"2008","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.biopha.2025.118262_bib43","doi-asserted-by":"crossref","first-page":"13482","DOI":"10.1074\/jbc.M117.780296","article-title":"Selective imaging of internalized proteopathic alpha-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies","volume":"292","author":"Karpowicz","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118262_bib44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.coi.2008.05.010","article-title":"When binding is enough: nonactivating antibody formats","volume":"20","author":"Labrijn","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2025.118262_bib45","first-page":"132","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2023","volume":"7","author":"Strohl","year":"2024","journal-title":"Antib. Ther."},{"key":"10.1016\/j.biopha.2025.118262_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12974-017-1050-z","article-title":"Fc gamma receptors are expressed in the developing rat brain and activate downstream signaling molecules upon cross-linking with immune complex","volume":"15","author":"Stamou","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2025.118262_bib47","unstructured":"Nielsen Soderberg J. Kallunki P., Buur L., Larsen F., Rajesh Kumar Parshad H., Sofie Markussen A., Manning M.C., Katayama, S., Gauden M., Smith J. (2024) Compositions and methods for treating synucleinopathies. Patent Application US2024\/0025979A1."},{"key":"10.1016\/j.biopha.2025.118262_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neuroscience.2011.10.042","article-title":"\u03b1-Synuclein phosphorylation and truncation are normal events in the adult human brain","volume":"200","author":"Muntane","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2025.118262_bib49","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1021\/acs.jproteome.8b00982","article-title":"Mass spectrometric analysis of Lewy body-enriched \u03b1, synuclein in Parkinson\u2019s disease","volume":"18","author":"Bhattacharjee","year":"2019","journal-title":"J. Proteome Res"},{"key":"10.1016\/j.biopha.2025.118262_bib50","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1073\/pnas.0406976102","article-title":"Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson\u2019s disease-linked mutations","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118262_bib51","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1074\/jbc.REV120.011743","article-title":"The emerging role of \u03b1-synuclein truncation in aggregation and disease","volume":"295","author":"Sorrentino","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118262_bib52","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","article-title":"Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: a phase 1 placebo-controlled trial","volume":"30","author":"Eijsvogel","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2025.118262_bib53","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118262_bib54","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.copbio.2014.06.013","article-title":"Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics","volume":"30","author":"Ju","year":"2014","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.biopha.2025.118262_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1304365","article-title":"Impact of structural modifications of IgG antibodies on effector functions","volume":"14","author":"Damelang","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118262_bib56","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/intimm\/dxh162","article-title":"The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge","volume":"16","author":"Ferrant","year":"2004","journal-title":"Int Immunol."},{"key":"10.1016\/j.biopha.2025.118262_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/imr.12349","article-title":"Human IgG4: a structural perspective","volume":"268","author":"Davies","year":"2015","journal-title":"Immunol. Rev."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:00:16Z","timestamp":1762311616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":57,"alternative-id":["S0753332225004561"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118262","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative assessment of binding and functional differences of clinical antibodies targeting \u03b1-synuclein in cellular models of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118262"}}